CL2020001791A1 - Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. - Google Patents

Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.

Info

Publication number
CL2020001791A1
CL2020001791A1 CL2020001791A CL2020001791A CL2020001791A1 CL 2020001791 A1 CL2020001791 A1 CL 2020001791A1 CL 2020001791 A CL2020001791 A CL 2020001791A CL 2020001791 A CL2020001791 A CL 2020001791A CL 2020001791 A1 CL2020001791 A1 CL 2020001791A1
Authority
CL
Chile
Prior art keywords
cerdulatinib
pharmaceutical compositions
topical skin
skin pharmaceutical
disclosed
Prior art date
Application number
CL2020001791A
Other languages
English (en)
Inventor
Charles Rodney Greenaway Evans
Cameron Robert Stevenson
Marc Barry Brown
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of CL2020001791A1 publication Critical patent/CL2020001791A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan formas de realización de formulaciones tópicas para administrar cerdulatinib o una sal, hidrato o solvato aceptable desde el punto de vista farmacéutico de este. También se divulgan formas de realización de métodos para preparar las formulaciones tópicas. Las formulaciones divulgadas son adecuadas para el tratamiento de afecciones dermatológicas tales como dermatitis atópica.
CL2020001791A 2018-01-09 2020-07-03 Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas. CL2020001791A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862615261P 2018-01-09 2018-01-09
US201862686509P 2018-06-18 2018-06-18
US201862765133P 2018-08-16 2018-08-16
US201862772415P 2018-11-28 2018-11-28

Publications (1)

Publication Number Publication Date
CL2020001791A1 true CL2020001791A1 (es) 2020-12-04

Family

ID=65685834

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001791A CL2020001791A1 (es) 2018-01-09 2020-07-03 Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.

Country Status (17)

Country Link
US (1) US20200390689A1 (es)
EP (1) EP3737354A2 (es)
JP (1) JP2021510159A (es)
KR (1) KR20200108297A (es)
CN (1) CN111818910A (es)
AU (1) AU2019208049A1 (es)
BR (1) BR112020013976A2 (es)
CA (1) CA3087124A1 (es)
CL (1) CL2020001791A1 (es)
CO (1) CO2020008244A2 (es)
IL (1) IL275899A (es)
MX (1) MX2020007062A (es)
RU (1) RU2020124293A (es)
SG (1) SG11202005781WA (es)
TW (1) TW201938167A (es)
WO (1) WO2019138291A2 (es)
ZA (1) ZA202004104B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3810144A4 (en) * 2018-06-04 2022-08-17 Chemistryrx TOPICAL HAIR GROWTH STIMULATING COMPOSITIONS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003244098A1 (en) 2002-06-28 2004-01-19 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxa mide derivative
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2574168B9 (en) * 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
AU2012241018B2 (en) * 2011-04-08 2015-11-12 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
JP6247223B2 (ja) * 2011-12-08 2017-12-13 ライジェル ファーマシューティカルズ， インコーポレイテッド 化合物を投与するための局所用製剤
KR20180002838A (ko) * 2015-05-07 2018-01-08 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 모발 생장을 촉진하기 위한 방법 및 조성물
WO2017027829A1 (en) * 2015-08-12 2017-02-16 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
CN108367006B (zh) * 2015-12-04 2021-12-31 博尔托拉制药公司 用于治疗血液癌症的赛度替尼
BR112018075202A2 (pt) * 2016-06-07 2019-03-19 Dermavant Sciences GmbH formulação tópica e método de tratamento de uma condição dermatológica em um sujeito
US11957931B2 (en) * 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo

Also Published As

Publication number Publication date
TW201938167A (zh) 2019-10-01
JP2021510159A (ja) 2021-04-15
BR112020013976A2 (pt) 2020-12-08
CO2020008244A2 (es) 2020-10-30
US20200390689A1 (en) 2020-12-17
SG11202005781WA (en) 2020-07-29
AU2019208049A1 (en) 2020-07-23
WO2019138291A3 (en) 2019-08-22
KR20200108297A (ko) 2020-09-17
CN111818910A (zh) 2020-10-23
CA3087124A1 (en) 2019-07-18
MX2020007062A (es) 2021-03-09
IL275899A (en) 2020-08-31
EP3737354A2 (en) 2020-11-18
WO2019138291A2 (en) 2019-07-18
ZA202004104B (en) 2022-01-26
RU2020124293A (ru) 2022-02-10

Similar Documents

Publication Publication Date Title
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
NI201900102A (es) Compuestos inhibidores de ask1 y usos de los mismos
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CL2019003091A1 (es) Terapia de combinación.
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2020000747A1 (es) Formulaciones de niraparib.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
CO2021000923A2 (es) Formulaciones de un inhibidor de axl/mer
AR086800A1 (es) Composicion farmaceutica oftalmologica topica que contiene regorafenib
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
WO2017091767A3 (en) Drug formulations for cancer treatment
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
MX2022013450A (es) Formulaciones farmaceuticas.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
BR112018071363A2 (pt) composições farmacêuticas orais de nicotinamida
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
CO2018011797A2 (es) Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação